gsk201508036k2.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending August 2015
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc
Notification of Transactions of Directors and Persons Discharging Managerial Responsibilities or Connected Persons
The table below sets out changes in the interests of a Connected Person of a Person Discharging Managerial Responsibilities ('PDMR') in the Ordinary Shares of GlaxoSmithKline plc ('GSK') arising from the pro-rata cancellation of an award granted in 2014 under the GlaxoSmithKline 2009 Performance Share Plan ('PSP').
This pro-rata cancellation was made in accordance with the PSP rules on leavers following the PDMR's Connected Person's termination of employment from GSK on 10 February 2015.
|
Name of PDMR
|
Name of Connected Person
|
Number of Ordinary Shares cancelled under a PSP award in accordance with leaver rules
|
|
Mr P Thomson
|
Mrs K Thomson
|
684.056
|
The Company was advised of this transaction on 31 July 2015.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
V A Whyte
Company Secretary
3 August 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: August 03, 2015
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc